BR0307394A - Derivados de metileno amida substituìda como moduladores de proteìnas tirosinas fosfatases (ptps), uso de um derivado de metileno amida substituìda, composição farmacêutica contendo pelo menos um derivado de metileno amida substituìda e método de preparação de um derivado de metileno amida substituìda - Google Patents
Derivados de metileno amida substituìda como moduladores de proteìnas tirosinas fosfatases (ptps), uso de um derivado de metileno amida substituìda, composição farmacêutica contendo pelo menos um derivado de metileno amida substituìda e método de preparação de um derivado de metileno amida substituìdaInfo
- Publication number
- BR0307394A BR0307394A BR0307394-7A BR0307394A BR0307394A BR 0307394 A BR0307394 A BR 0307394A BR 0307394 A BR0307394 A BR 0307394A BR 0307394 A BR0307394 A BR 0307394A
- Authority
- BR
- Brazil
- Prior art keywords
- substituted methylene
- methylene amide
- amide derivative
- ptps
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/56—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having carbon atoms of carboxamide groups bound to carbon atoms of carboxyl groups, e.g. oxamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/06—1,2,3-Thiadiazoles; Hydrogenated 1,2,3-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/58—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/34—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Abstract
"DERIVADOS DE METILENO AMIDA SUBSTITUìDA COMO MODULADORES DE PROTEìNAS TIROSINAS FOSFATASES (PTPS) , USO DE UM DERIVADO DE METILENO AMIDA SUBSTITUìDA, COMPOSIçãO FARMACêUTICA CONTENDO PELO MENOS UM DERIVADO DE METILENO AMIDA SUBSTITUìDA E MéTODO DE PREPARAçãO DE UM DERIVADO DE METILENO AMIDA SUBSTITUìDA". Sendo que a presente invenção refere-se a derivados de metileno amida substituída de fórmula (I) e uso dos mesmos para o tratamento e/ou prevenção de desordens metabólicas mediadas por resistência à insulina ou hiperglicemia, compreendendo diabetes do tipo I e/ou II, tolerância inadequada à glicose, resistência à insulina, hiperlipidemia, hipertrigliceridemia, hipercolesterolemia, obesidade, síndrome do ovário policístico (PCOS). Em especial a presente invenção refere-se ao uso de derivados de metileno amida substituída de fórmula (I) para modular e, principalmente, para inibir a atividade de PTPs. Além disso, a presente invenção refere-se a um método de tratamento de diabetes do tipo II, obesidade e regulação do apetite de mamíferos. A presente invenção refere-se adicionalmente a novos derivados de metileno amida substituída e a um método de preparação dos mesmos. Fórmula (I).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02100078 | 2002-01-29 | ||
EP02100410 | 2002-04-25 | ||
PCT/EP2003/000808 WO2003064376A1 (en) | 2002-01-29 | 2003-01-27 | Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases (ptps) |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0307394A true BR0307394A (pt) | 2004-11-09 |
Family
ID=27664997
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0307394-7A BR0307394A (pt) | 2002-01-29 | 2003-01-27 | Derivados de metileno amida substituìda como moduladores de proteìnas tirosinas fosfatases (ptps), uso de um derivado de metileno amida substituìda, composição farmacêutica contendo pelo menos um derivado de metileno amida substituìda e método de preparação de um derivado de metileno amida substituìda |
Country Status (24)
Country | Link |
---|---|
US (1) | US7592477B2 (pt) |
EP (1) | EP1470102B1 (pt) |
JP (2) | JP4828793B2 (pt) |
KR (1) | KR100922041B1 (pt) |
CN (1) | CN100410236C (pt) |
AT (1) | ATE510817T1 (pt) |
AU (1) | AU2003239296B2 (pt) |
BR (1) | BR0307394A (pt) |
CA (1) | CA2472021C (pt) |
CY (1) | CY1111576T1 (pt) |
DK (1) | DK1470102T3 (pt) |
EA (1) | EA012260B1 (pt) |
HK (1) | HK1073649A1 (pt) |
HR (1) | HRP20040612A2 (pt) |
IL (1) | IL163144A (pt) |
MX (1) | MXPA04007253A (pt) |
NO (1) | NO329742B1 (pt) |
PL (1) | PL207295B1 (pt) |
PT (1) | PT1470102E (pt) |
RS (1) | RS51865B (pt) |
SI (1) | SI1470102T1 (pt) |
UA (1) | UA82661C2 (pt) |
WO (1) | WO2003064376A1 (pt) |
ZA (1) | ZA200405179B (pt) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1656139E (pt) * | 2003-07-21 | 2011-11-04 | Merck Serono Sa | Arildicarboxamidas |
WO2005012280A1 (en) * | 2003-07-21 | 2005-02-10 | Applied Research Systems Ars Holding N.V. | Alkynyl aryl carboxamides |
ATE381529T1 (de) | 2003-10-13 | 2008-01-15 | Serono Lab | Verfahren zur herstellung von para-phenylalkynyl benzaldehyden |
EA011811B1 (ru) * | 2004-02-27 | 2009-06-30 | Лаборатуар Сероно Са | Применение производных метиленамида при лечении сердечно-сосудистых нарушений |
AU2005231980B2 (en) * | 2004-04-07 | 2011-09-08 | Merck Serono Sa | 1,1'-(1,2-ethynediyl)bis-benzene derivatives as PTP 1-B inhibitors |
CN1942428A (zh) | 2004-04-13 | 2007-04-04 | 默克公司 | Cetp抑制剂 |
US7517991B2 (en) * | 2004-10-12 | 2009-04-14 | Bristol-Myers Squibb Company | N-sulfonylpiperidine cannabinoid receptor 1 antagonists |
WO2007009959A1 (en) * | 2005-07-15 | 2007-01-25 | Laboratoires Serono S.A. | Glepp-1 inhibitors in the treatment of autoimmune and/or inflammatory disorders |
WO2007028145A2 (en) * | 2005-09-02 | 2007-03-08 | Dara Biosciences, Inc. | Agents and methods for reducing protein tyrosine phosphatase 1b activity in the central nervous system |
US7888376B2 (en) | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
JP5773560B2 (ja) | 2006-02-09 | 2015-09-02 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | Cetp阻害剤のポリマー製剤 |
JP2009526773A (ja) * | 2006-02-13 | 2009-07-23 | ラボラトワール セローノ ソシエテ アノニム | 細菌感染症治療のためのスルホンアミド誘導体 |
WO2008044731A1 (fr) * | 2006-10-12 | 2008-04-17 | Institute Of Medicinal Molecular Design. Inc. | Dérivé d'acide n-phényloxamidique |
US8633245B2 (en) * | 2008-04-11 | 2014-01-21 | Institute Of Medicinal Molecular Design, Inc. | PAI-1 inhibitor |
EP2602839A1 (en) | 2010-08-05 | 2013-06-12 | Idemitsu Kosan Co., Ltd. | Organic electroluminescent element |
CN102512407B (zh) * | 2011-11-23 | 2014-05-21 | 中山大学 | 一种β-苯丙氨酸类化合物作为醛糖还原酶抑制剂的应用 |
EP2917194B1 (en) * | 2012-11-06 | 2017-09-27 | Eli Lilly and Company | Novel benzyl sulfonamide compounds useful as mogat-2 inhibitors |
US10647664B2 (en) * | 2013-08-16 | 2020-05-12 | Duke University | Substituted hydroxamic acid compounds |
JP7454573B2 (ja) * | 2018-11-23 | 2024-03-22 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | インスリン抵抗性を処置するためのshp2阻害剤の使用 |
CN115297860A (zh) * | 2020-04-06 | 2022-11-04 | 普渡研究基金会 | 新型n-芳基草氨酸 |
CN114478522B (zh) * | 2022-01-25 | 2023-07-28 | 山东大学 | 一种吡啶并咪唑类衍生物及其制备方法与应用 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5217482A (en) * | 1975-07-25 | 1977-02-09 | Sumitomo Chem Co Ltd | Preparation of quinazolinone derivatives |
AU641052B2 (en) * | 1990-11-02 | 1993-09-09 | Aventisub Ii Inc. | 3-amidoindolyl derivatives |
ATE233240T1 (de) | 1994-12-02 | 2003-03-15 | Yamanouchi Pharma Co Ltd | Neues amidinonaphthylderivat oder dessen salz |
JPH08295667A (ja) * | 1995-04-27 | 1996-11-12 | Takeda Chem Ind Ltd | 複素環化合物、その製造法および剤 |
JP3283485B2 (ja) * | 1998-04-10 | 2002-05-20 | 日本たばこ産業株式会社 | アミジン化合物 |
US6488973B1 (en) * | 1998-10-05 | 2002-12-03 | Food Talk, Inc. | Method of making a cooking pouch containing a raw protein portion, a raw or blanched vegetable portion and a sauce |
EP1123928A4 (en) * | 1998-10-20 | 2005-02-16 | Takeda Pharmaceutical | 1,5-BENZODIAZEPINE COMPOUNDS, PROCESS FOR PRODUCING THE SAME, AND MEDICAMENT |
JP2003509429A (ja) * | 1999-09-10 | 2003-03-11 | ノボ ノルディスク アクティーゼルスカブ | タンパク質チロシンホスファターゼ(ptpアーゼ)のモジュレーター |
WO2002018321A2 (en) * | 2000-08-29 | 2002-03-07 | Abbott Laboratories | Amino(oxo)acetic acid protein tyrosine phosphatase inhibitors |
US6627767B2 (en) * | 2000-08-29 | 2003-09-30 | Abbott Laboratories | Amino(oxo) acetic acid protein tyrosine phosphatase inhibitors |
WO2002100396A1 (en) | 2001-06-07 | 2002-12-19 | Wyeth | COMBINATION OF A PTPase INHIBITOR AND A THIAZOLIDINEDIONE AGENT |
EA011811B1 (ru) * | 2004-02-27 | 2009-06-30 | Лаборатуар Сероно Са | Применение производных метиленамида при лечении сердечно-сосудистых нарушений |
-
2003
- 2003-01-27 BR BR0307394-7A patent/BR0307394A/pt not_active IP Right Cessation
- 2003-01-27 CN CNB038070367A patent/CN100410236C/zh not_active Expired - Fee Related
- 2003-01-27 CA CA2472021A patent/CA2472021C/en not_active Expired - Fee Related
- 2003-01-27 US US10/501,344 patent/US7592477B2/en not_active Expired - Fee Related
- 2003-01-27 DK DK03734697.0T patent/DK1470102T3/da active
- 2003-01-27 PL PL371198A patent/PL207295B1/pl not_active IP Right Cessation
- 2003-01-27 EP EP03734697A patent/EP1470102B1/en not_active Expired - Lifetime
- 2003-01-27 UA UA20040706337A patent/UA82661C2/uk unknown
- 2003-01-27 AT AT03734697T patent/ATE510817T1/de active
- 2003-01-27 PT PT03734697T patent/PT1470102E/pt unknown
- 2003-01-27 MX MXPA04007253A patent/MXPA04007253A/es active IP Right Grant
- 2003-01-27 RS YU65304A patent/RS51865B/sr unknown
- 2003-01-27 SI SI200332010T patent/SI1470102T1/sl unknown
- 2003-01-27 AU AU2003239296A patent/AU2003239296B2/en not_active Ceased
- 2003-01-27 WO PCT/EP2003/000808 patent/WO2003064376A1/en active Application Filing
- 2003-01-27 KR KR1020047011772A patent/KR100922041B1/ko not_active IP Right Cessation
- 2003-01-27 JP JP2003564000A patent/JP4828793B2/ja not_active Expired - Fee Related
- 2003-01-27 EA EA200400882A patent/EA012260B1/ru not_active IP Right Cessation
-
2004
- 2004-06-29 ZA ZA2004/05179A patent/ZA200405179B/en unknown
- 2004-07-06 HR HR20040612A patent/HRP20040612A2/xx not_active Application Discontinuation
- 2004-07-22 IL IL163144A patent/IL163144A/en not_active IP Right Cessation
- 2004-08-24 NO NO20043520A patent/NO329742B1/no not_active IP Right Cessation
-
2005
- 2005-08-30 HK HK05107572A patent/HK1073649A1/xx not_active IP Right Cessation
-
2011
- 2011-06-16 CY CY20111100576T patent/CY1111576T1/el unknown
- 2011-06-30 JP JP2011146082A patent/JP2011256174A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
RS51865B (sr) | 2012-02-29 |
CY1111576T1 (el) | 2015-10-07 |
KR100922041B1 (ko) | 2009-10-19 |
CA2472021C (en) | 2012-08-14 |
IL163144A (en) | 2012-07-31 |
US7592477B2 (en) | 2009-09-22 |
ATE510817T1 (de) | 2011-06-15 |
NO20043520L (no) | 2004-10-05 |
DK1470102T3 (da) | 2011-06-20 |
ZA200405179B (en) | 2005-08-31 |
CN100410236C (zh) | 2008-08-13 |
EA200400882A1 (ru) | 2005-04-28 |
WO2003064376A1 (en) | 2003-08-07 |
NO329742B1 (no) | 2010-12-13 |
EA012260B1 (ru) | 2009-08-28 |
EP1470102A1 (en) | 2004-10-27 |
MXPA04007253A (es) | 2004-10-29 |
KR20040104953A (ko) | 2004-12-13 |
SI1470102T1 (sl) | 2011-08-31 |
PL371198A1 (en) | 2005-06-13 |
CN1633410A (zh) | 2005-06-29 |
HK1073649A1 (en) | 2005-10-14 |
JP2011256174A (ja) | 2011-12-22 |
PL207295B1 (pl) | 2010-11-30 |
US20050124656A1 (en) | 2005-06-09 |
AU2003239296B2 (en) | 2008-10-23 |
HRP20040612A2 (en) | 2005-04-30 |
JP4828793B2 (ja) | 2011-11-30 |
EP1470102B1 (en) | 2011-05-25 |
UA82661C2 (uk) | 2008-05-12 |
JP2005516061A (ja) | 2005-06-02 |
PT1470102E (pt) | 2011-06-06 |
CA2472021A1 (en) | 2003-08-07 |
RS65304A (en) | 2007-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0307394A (pt) | Derivados de metileno amida substituìda como moduladores de proteìnas tirosinas fosfatases (ptps), uso de um derivado de metileno amida substituìda, composição farmacêutica contendo pelo menos um derivado de metileno amida substituìda e método de preparação de um derivado de metileno amida substituìda | |
UA85405C2 (ru) | Производные 1,1'-(1,2-этиндиил)бис-бензола как ингибиторы ртр-1в | |
BR0313266A (pt) | Compostos, respectivos processos de preparação e uso, formulação farmacêutica e métodos de prevenção e/ou tratamento de um distúrbio mediado pelo receptor de mglur5 e de inibição da ativação de receptores de mglur5 | |
DE602007007614D1 (de) | Substituierte pyrrolidinone als hemmer von 11-beta-hydroxysteroiddehydrogenase 1 | |
BR0009486A (pt) | Compostos que contêm uma amida, utilização desses compostos, composição farmacêutica, processo para o tratamento profilático ou terapêutico de, diabetes do tipo ii e processo para a preparação dos compostos | |
CY1112398T1 (el) | Πυρρολιδινονες υποκατασταθεισες απο κυκλοεξυλιο ως αναστολεις της 11-β-υδροξυστεροειδικης αφυδρογονασης 1 | |
BR0315047A (pt) | Composto, composição fermacêutica que compreende o mesmo, processo para a preparação da composição farmacêutica, utilização dos compostos, método de tratamento e processo para a preparação do composto | |
EA200400226A1 (ru) | Новые пирролы, обладающие гиполипидемической и гипохолестеринемической активностью, способ их получения и содержащие их фармацевтические композиции и их применение в медицине | |
BRPI0507198A (pt) | derivados de bisariluréia | |
BRPI0517423A (pt) | composto, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psiquiátricos associados com disfunção do glutamato em um animal, e, uso em um composto | |
BRPI0507104A (pt) | n-ciclohexilimidazolinonas substituìdas com efeito modulador de mch | |
SE9702457D0 (sv) | Screening | |
BRPI0614168A2 (pt) | Composto ou um sal, hidrato, solvato, isoforma, tautômero, isômero óptico farmaceuticamente aceitável ou uma combinação dos mesmos, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psquiátricos, uso de um composto, e, processo para a preparação de um composto | |
BR0015466A (pt) | Composto, prodroga, composição farmacêutica, agentes para evitar ou tratar diabetes mellitus, hiperlipidemia e toler ncia à glicose prejudicada, para regular a função do receptor relacionado a retinóide e para melhorar a resistência à insulina e uso de um composto | |
BRPI0507481A (pt) | composto, composição farmacêutica, uso do composto, e, métodos para tratar distúrbios mediados por mglur 5 e para inibir ativação de receptores de mglur 5 | |
EA200870489A1 (ru) | Пиперидинилзамещённые пирролидиноны в качестве ингибиторов 11-бета-гидроксистероид дегидрогеназы 1 | |
EA200870462A1 (ru) | Производные бифениламидлактама в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы 1 | |
DE602004017174D1 (de) | Phenoxyessigsäure-derivate zur behandlung von störungen der atemwege | |
EA200800081A1 (ru) | Бензамидные производные (варианты), содержащая их фармацевтическая композиция (варианты), способ лечения заболеваний, связанных с модуляцией гидроксистероиддегидрогеназ на основе указанных производных(варианты) | |
BR9906796A (pt) | Método para a administração de análogos de insulina monoméricos | |
EA200501710A1 (ru) | Замещённые карбоновые кислоты | |
MY142983A (en) | Pyrrolopyridine derivatives and use of same as ppar receptor modulators | |
BR0208688A (pt) | Lipìdeo diminuindo bifenil carboxamidas | |
BRPI0407968A (pt) | derivados de oxamida úteis como inibidores de raf-quinase | |
BRPI0403028A (pt) | Compostos heterocìclicos de oxima, processo para sua preparação e composições farmacêuticas contendo os mesmos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: LABORATOIRES SERONO S.A. (CH) Free format text: TRANSFERIDO DE: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B25D | Requested change of name of applicant approved |
Owner name: MERCK SERONO S.A. (CH) |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 13A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |